News Desk
A Turning Point in Global Product Liability Litigation
In a significant development for thousands of women worldwide, including those in India keenly observing international legal precedents, a U.S. court-appointed special master has recommended allowing expert testimony linking Johnson & Johnson’s (J&J) talc products to ovarian cancer. This decision, emerging from extensive litigation in the federal court in New Jersey, paves the way for potential trials later this year, marking a crucial moment for consumers and product safety advocates globally.
Retired U.S. District Judge Freda Wolfson, overseeing litigation involving over 67,500 lawsuits, issued the recommendation. Such product liability cases heavily rely on expert evidence to establish a causal link between a product and alleged harm, making these decisions pivotal. The ruling is a recommendation to U.S. District Judge Michael Shipp, who will make the final determination after considering objections.
Expert Testimony Deemed Reliable
A key aspect of Wolfson’s extensive 658-page decision was her finding that plaintiffs’ experts can indeed testify about a causal link between J&J talc products and cancer, a claim the company vigorously disputes. “I find, by a preponderance of the evidence, that the Plaintiffs’ experts have applied reliable methodologies to arrive at their opinions that the pre- and post-2020 epidemiologic studies, taken as a whole, demonstrate a positive, statistically significant association between genital talc powder use and ovarian cancer,” Wolfson stated.
Notably, Wolfson also approved testimony from experts presented by J&J to counter these claims. Her role, she clarified, was to assess the reliability of methods, not to evaluate the experts’ conclusions themselves, leaving that for a jury. However, she agreed with J&J to exclude testimony linking heavy metals and fragrance chemicals in the products to cancer, and a theory about inhaled talc migrating to ovaries.
J&J Plans Appeal; Indian Consumers Watch Closely
In response, Erik Haas, J&J Worldwide Vice President of Litigation, declared Wolfson’s ruling “erroneous” and confirmed the company’s intent to appeal to Judge Shipp. Haas emphasized the “gatekeeping duty” of judges to ensure reliability in expert opinions. Following the announcement, shares of J&J experienced a marginal dip of 0.4% in after-hours trading.
For years, J&J has maintained the safety of its products and denied any cancer link, ceasing sales of talc-based baby powder in the U.S. in 2020 to transition to a cornstarch alternative. This ongoing legal battle has significant resonance in India, a major consumer market where product safety standards and legal recourse for consumers are increasingly under scrutiny. Many Indian families have historically used talc-based products, and the outcomes of these U.S. litigations could influence future consumer protection actions and awareness campaigns across the subcontinent.
Re-evaluation and Rule Changes
This marks the second instance of Wolfson reviewing the scientific evidence in this case, having previously sided with plaintiffs in 2020 regarding asbestos contamination. In 2024, Judge Shipp requested a re-evaluation due to recent changes in federal rules strengthening judicial oversight of expert testimony and the emergence of new scientific evidence.
J&J’s attempts to resolve the litigation through bankruptcy have been repeatedly rejected by federal courts, most recently in April 2025, effectively holding many talc product cases in abeyance for years. The company also engaged in legal actions against scientists whose research supported plaintiffs’ cases, alleging falsification of results. While one such lawsuit is pending, another has been dismissed.
Mixed Record and Substantial Verdicts
Prior to bankruptcy efforts, J&J faced a mixed record in state courts. Some trials saw verdicts as high as $4.69 billion awarded to 22 women for ovarian cancer claims, though some of these have been reduced on appeal. J&J has also won some trials outright.
Separately, J&J continues to contend with cases alleging its talc products caused mesothelioma, a rare and aggressive cancer. While some of these claims have been settled, a nationwide settlement has not been reached, leading to numerous state court trials. The past year has seen several substantial mesothelioma verdicts against J&J, including a staggering more than $1.5 billion in Baltimore in December.
Plaintiffs’ Lawyers See Justice Approaching
Chris Tisi, a lawyer representing the plaintiffs, stated that Wolfson’s report affirms the “sound evidence that Johnson’s Baby Powder can cause ovarian cancer.” He expressed gratitude that “after all of J&J’s delays, these women and their families will finally have their day in court,” a sentiment echoed by consumer advocacy groups globally, including those in India fighting for greater corporate accountability.
Alok Kumar
